European Society of Cardiology (ESC) Congress 2026

Munich, Germany & Online 28 August 2026 - 31 August 2026

Fewer major bleeds with prasugrel as default antiplatelet after PCI

04 Oct 2026 by

When prasugrel is the default antiplatelet for patients with acute coronary syndromes (ACS) undergoing PCI*, fewer major bleeds occur than when ticagrelor is the default, according to the SWITCH-SWEDEHEART study presented at ESC 2026. This benefit is not accompanied by increased ischaemic events.

04 Oct 2026

Early PCSK9 inhibition post-MI lowers LDL-C: Does it influence clinical outcomes?

03 Oct 2026 by

Initiating the PCSK9* inhibitor evolocumab in the cath lab prior to PCI** in patients with acute myocardial infarction (MI) dramatically lowers LDL-C compared with standard care in the phase IV AMUNDSEN trial presented at ESC 2026.

03 Oct 2026

TAVI before PCI a viable strategy for severe aortic stenosis, CAD

03 Oct 2026 by

A transcatheter aortic-valve implantation (TAVI)-first strategy is noninferior to the standard percutaneous coronary intervention (PCI)-first approach in terms of clinical outcomes at 1 year in patients with severe aortic stenosis and concomitant coronary artery disease (CAD), according to the TAVI PCI trial presented at ESC 2026.

03 Oct 2026

Aficamten shows promise for nonobstructive HCM

25 Sep 2026 by

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.

25 Sep 2026

AI + mammography: A new gateway for CVD detection?

15 Sep 2026 by

A retrospective analysis presented at ESC 2026 demonstrates the ability of artificial intelligence (AI) to detect cardiovascular diseases (CVDs) from routine mammograms.

15 Sep 2026

Healthy seniors get cardioprotective benefit with statins

14 Sep 2026 by

Use of statins in the primary prevention setting yields a substantial reduction in the risk of major cardiovascular events in community-dwelling adults at least 70 years of age, as shown in the STAREE trial.

14 Sep 2026

Aficamten retains upper hand over metoprolol for oHCM in subanalysis

14 Sep 2026 by

Results from a subanalysis of the MAPLE-HCM* trial presented at ESC 2026 continue to support the superiority of aficamten over metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) irrespective of beta-blocker (BB) use at screening and prior standard-of-care (SoC) status.

14 Sep 2026

Novel oral relaxin receptor agonist shows promise in chronic heart failure

12 Sep 2026 by

In patients with chronic heart failure (HF), the addition of the oral relaxin family peptide receptor 1 (RXFP1) agonist AZD5462 to guideline-directed medical therapies (GDMTs) may help improve cardiac remodelling and haemodynamics across a wide range of left ventricular ejection fraction (LVEF), according to the phase IIb LUMINARA study.

12 Sep 2026

Inclisiran outdoes BPA for LDL-C lowering in high CV risk patients

11 Sep 2026 by

In the phase IV VICTORION-Challenge trial, inclisiran outperforms bempedoic acid (BPA) for lowering LDL-C in individuals with high and very high cardiovascular (CV) risk.

11 Sep 2026

SHASTA trials boost plozasiran potential in severe hypertriglyceridaemia

10 Sep 2026 by

In the SHASTA-3 and SHASTA-4 trials, quarterly administration of plozasiran reduced triglyceride (TG) levels and acute pancreatitis (AP) events in individuals with severe hypertriglyceridaemia (sHTG; TG ≥500 mg/dL).

10 Sep 2026